Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously announced information resolved to carry out a directed issue of in total 1,017,488,260 shares.


31 juli, 21:00

The share issues has resulted in a change of the registered share capital and shares and votes in Xbrane. As of 31 July 2025, the total number of shares and votes in the Company amounts to 2,549,678,555. The Company's registered share capital amounts to approximately SEK 571,602,393.

Contacts

Martin Åmark, CEO
E: martin.amark@xbrane.com

Jane Benyamin, CFO/IR
E: jane.benyamin@xbrane.com

About Us

Xbrane Biopharma AB develops biological drugs based on a patented platform technology that provides significantly lower production costs compared to competing systems. Xbrane has a portfolio of biosimilar candidates targeting EUR 23 billion in estimated annual peak sales of the respective reference product. The lead candidate Ximluci® is granted market authorization approval in Europe and was launched during 2023. Xbrane’s head office is in Solna, just outside Stockholm. Xbrane is listed on Nasdaq Stockholm under the ticker XBRANE. For more information, visit www.xbrane.com

This information is information that Xbrane Biopharma is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-07-31 21:00 CEST.

Attachments

Xbrane Biopharma AB (“Xbrane” or the “Company”) has according to previously announced information resolved to carry out a directed issue of in total 1,017,488,260 shares.

Läs mer på MFN

Ämnen i artikeln


Xbrane Biopharma

Senast

0,27

1 dag %

−2,95%

1 dag

1 mån

1 år

Marknadsöversikt

1 DAG %

Senast

1 mån
Senaste aktieanalyserna på Placera
Kollage Analys Ny
Privatekonomi med Placeras expert
Karolina Placera

Karolina Palutko Macéus skriver om allt som har med privatekonomi att göra och hur du kan få mer pengar i plånboken.

Affärsvärlden
AFV

Är du kund hos Avanza? Just nu kan du få en unik rabatt på Affärsvärlden. Afv har 28 år i rad utsetts till Sveriges bästa affärsmagasin i en undersökning med börs-VD:ar, finanschefer, IR-chefer och aktieproffs.

Annons
Introduce

för börsens små- och medelstora företag.

Annons
Investtech

Här hittar du våra artiklar om teknisk analys i samarbete med Investtech.